Cognition Disorders

Abstract

Cognition disorders are conditions in which acquired damage or disease degrades one or more domains of thinking, such as memory, attention, language, executive control, perceptual-motor skill, or social cognition, beyond what normal aging explains. The modern framework, set out in the DSM-5, arranges them on a single severity continuum: a mild neurocognitive disorder when deficits are measurable yet everyday independence is preserved, and a major one, long called dementia, when they compromise it, with acute, fluctuating delirium as a separate syndrome. This article traces that continuum, the six cognitive domains that define it, the screening and biomarker tools that detect it, and the base-rate reasoning that governs their interpretation. Three interactive demonstrations let the reader place a deficit on the mild/major boundary, weigh a positive screen against its base rate, and watch mild impairment convert to dementia over time.

Keywords: neurocognitive disorder, mild cognitive impairment, dementia

Cognition disorders are acquired conditions in which brain injury or disease measurably degrades one or more domains of thinking, from an isolated failure of memory to a broad collapse of reasoning, language, and judgment, always as a decline from a person's own former level rather than a lifelong low ceiling (Sachdev et al., 2014). In the Medical Subject Headings vocabulary the category is catalogued among the mental disorders as cognition disorders, and, as the name states, these are disorders of cognition itself, of the very processes of perceiving, remembering, and reasoning that the rest of this site treats as normal function. What makes the category coherent, rather than a loose list of diseases, is the framework the fifth edition of the Diagnostic and Statistical Manual imposed on it: a single graded spectrum of severity, cut by the point at which deficits begin to cost a person their independence, with the acute confusion of delirium set apart as a syndrome of its own (Ganguli et al., 2011). The sections below set out that framework, the domains it is built from, the tools that detect it, the diseases and biomarkers beneath it, the special case of delirium, and the base-rate logic without which a positive test is easily misread.

The Rise of the Neurocognitive Disorder

For most of the twentieth century the vocabulary of acquired cognitive decline was a patchwork: dementia for the severe and progressive loss of the old, amnestic and other syndromes for focal deficits, and organic brain syndrome as a catch-all that carried more stigma than information. The fifth edition of the Diagnostic and Statistical Manual, published in 2013, replaced this with a single ordered family, the neurocognitive disorders, defined not by cause in the first instance but by severity and by the domains affected (American Psychiatric Association, 2013). The decisive move was to make the disorders graded rather than categorical. Instead of a person either having dementia or not, the manual recognises a mild neurocognitive disorder, in which cognition has objectively declined but the person still manages daily life, and a major neurocognitive disorder, the term that subsumes what was called dementia, in which the decline is severe enough to require help with everyday activities (Sachdev et al., 2014). This continuum was not an arbitrary tidying. It reflected two decades of evidence that measurable cognitive impairment often precedes frank dementia by years, and it created a diagnostic home for that prodromal stage so that it could be studied and, eventually, treated. The working group that drafted the scheme was explicit that it was a work in progress, a scaffold to be refined as the biology of the underlying diseases came into focus, rather than a finished natural classification (Ganguli et al., 2011).

Types of Cognition Disorders

Beyond being a subject in its own right, Cognition Disorders is a formal category in the National Library of Medicine's Medical Subject Headings, which places it at tree position F03.615.250, beneath Neurocognitive Disorders, and hangs its recognised narrower kinds beneath it. These subtypes are a classification built to index the literature, not a claim about the mind's natural joints; several are treated at length in their own articles. Table 2 lists the direct children of the descriptor.

Two cautions keep this taxonomy in its place. It is a classification for indexing, built to organise the literature, not a theory asserting these subtypes are mutually exclusive or an exhaustive set of natural kinds. And a MeSH subtype is a narrower topic, not a component process: listing a child under Cognition Disorders locates it in an index and says nothing, on its own, about the mechanisms this article describes.

The Six Cognitive Domains

A disorder of cognition has to be a disorder of some particular part of cognition, and the DSM-5 framework rests on an explicit inventory of six domains, so that a diagnosis names not just a decline but where the decline falls (Sachdev et al., 2014). The domains are complex attention, executive function, learning and memory, language, perceptual-motor function, and social cognition, and different diseases carve them differently: Alzheimer's disease characteristically opens with a failure of learning and memory, a frontotemporal degeneration with changes in social cognition or language, a vascular process with patchy losses of attention and executive control. Fixing the domains matters because it disciplines assessment, requiring that each be probed rather than that a single global score stand in for the whole of thought, and because the profile of spared and impaired domains is itself a clue to the disease beneath (Ganguli et al., 2011). Table 1 sets out the six with an everyday sign of impairment in each.

Table 1

The Six Cognitive Domains of the DSM-5 Neurocognitive Disorders

Note. The six domains are the DSM-5 inventory used to specify which part of cognition a disorder affects; the profile of spared and impaired domains helps point to the disease beneath (Sachdev et al., 2014; Ganguli et al., 2011).

The Mild-to-Major Continuum

The single most consequential feature of the modern scheme is that the boundary between a mild disorder and a major one is drawn by function, not by the test score. Two people can score identically on cognitive testing and receive different diagnoses: if one still pays the bills, manages medications, and travels independently while the other cannot, the first has a mild neurocognitive disorder and the second a major one (Sachdev et al., 2014). This is a deliberate inversion of the intuition that a diagnosis should follow the number. The clinical entity that occupies the mild band was described a decade before the DSM-5 adopted it, when Ronald Petersen and colleagues characterised mild cognitive impairment as a state of objective, usually memory-led decline in a person who nonetheless remains functionally independent and does not meet criteria for dementia (Petersen et al., 1999). Petersen later broadened the concept beyond its amnestic form and made it a diagnostic entity in its own right, a recognised waypoint rather than merely the earliest visible edge of dementia (Petersen, 2004). An international consensus soon consolidated mild cognitive impairment as the target for early detection and intervention, since it is at this stage, before independence is lost, that any disease-modifying treatment would do the most good (Gauthier et al., 2006). The criteria for the mild stage were later refined for research use, tied where possible to the biology of the underlying disease (Albert et al., 2011). Figure 1 shows the continuum, and the demonstration below lets the reader hold a score fixed and watch the diagnosis move as independence is gained or lost.

Screening and Assessment

Because the disorders are defined by decline across domains, detecting them starts with measurement, and the front line is the brief cognitive screen. The Mini-Mental State Examination, introduced by Marshal Folstein and colleagues in 1975, was the first such instrument to gain wide use, a short standardised battery giving a single score out of thirty that samples orientation, memory, attention, language, and construction (Folstein et al., 1975). Its very brevity is also its limit: it is relatively insensitive to the mild, executive, and visuospatial deficits that mark early or non-Alzheimer disease. The Montreal Cognitive Assessment, developed by Ziad Nasreddine and colleagues, was designed to close that gap, adding tasks that tax executive function, attention, and delayed recall, and it proved substantially more sensitive to mild cognitive impairment than the older screen (Nasreddine et al., 2005). Neither test diagnoses anything on its own. A screen is a triage instrument: it flags people who warrant fuller evaluation, which draws on detailed neuropsychological testing across all six domains, a corroborated history of change over time, and, increasingly, biomarkers of the disease beneath. The screen also carries a statistical trap that the next demonstration makes concrete, because the meaning of a positive result depends entirely on how common the disorder is among the people being tested.

Etiologies and Biomarkers

A neurocognitive disorder is a syndrome, a pattern of decline, and the same pattern can issue from many diseases: Alzheimer's disease, cerebrovascular disease, Lewy body disease, frontotemporal lobar degeneration, and others, often in combination in the aging brain. The most far-reaching recent change is that some of these causes can now be identified during life rather than only at autopsy. A research framework advanced by Clifford Jack and colleagues proposed defining Alzheimer's disease biologically, by biomarkers of amyloid plaques, tau tangles, and neurodegeneration, rather than by its clinical symptoms, so that the disease process and the cognitive syndrome it produces become separable objects of study (Jack et al., 2018). This decoupling matters for the whole category, because it means a cognitive syndrome can be traced to a specific pathology, and because the same pathology can be detected before the syndrome appears at all. It also complicates the clinical picture, since biomarker evidence of disease can be present in people whose cognition is still intact. The broader history of Alzheimer's disease, from its description to the present biomarker era, shows how a condition once diagnosable only by exclusion and confirmable only after death has become, in principle, a biologically defined entity (Bondi et al., 2017). For most patients, though, diagnosis still rests on the clinical picture, and biomarkers refine rather than replace it.

Delirium: The Acute Disorder

One member of the cognition-disorders family stands apart, and confusing it with the others is a costly error. Delirium is an acute, fluctuating disturbance of attention and awareness that develops over hours to days, in contrast to the chronic, gradual course of the neurocognitive disorders on the main continuum (Inouye et al., 2014). It is typically triggered by an acute insult, an infection, a metabolic disturbance, a drug, or surgery, most often in an older or already cognitively vulnerable person, and, crucially, it is frequently reversible once its cause is found and treated. That reversibility is why the distinction is not academic: delirium is a medical emergency to be investigated, not a fixed decline to be accepted. Yet it is easily missed, especially in its quiet, hypoactive form, and it interacts with the chronic disorders in both directions, since an existing dementia is the single largest risk factor for delirium and an episode of delirium in turn accelerates cognitive decline and can be the first visible sign of an underlying disease. Delirium is therefore drawn off the main severity axis in Figure 1: it is not a point on the mild-to-major continuum but a separate disturbance that can strike at any point along it, including in a previously healthy brain.

Progression and Prevention

If mild cognitive impairment is the waypoint before dementia, the natural question is how often the journey is completed, and the answer refuses to be a single number. Across studies a fraction of people with mild cognitive impairment progress to dementia each year, but a substantial share remain stable for years and some revert to normal cognition, so the label marks elevated risk rather than an appointment with a fixed outcome (Petersen, 2004). Because the yearly hazard compounds, even a modest annual rate accumulates into a considerable cumulative risk over a decade, which the final demonstration makes visible, while the curve still plateaus well below certainty. The complement of progression is prevention, and here the evidence has grown more hopeful. The Lancet Commission on dementia estimated that a large share of dementia cases worldwide is attributable to modifiable risk factors spread across the lifespan, among them less education in early life, hearing loss, hypertension, obesity, smoking, depression, physical inactivity, diabetes, and social isolation in later life (Livingston et al., 2020). None of this makes dementia preventable in the individual case, and acting on every risk factor shifts the odds rather than guaranteeing the outcome, but at the level of the population the implication is substantial: a meaningful portion of the burden is not fixed by fate.

Worked Example

The screening demonstration above turns on a single application of Bayes' theorem, and the arithmetic is worth working by hand because its result is so counterintuitive. Take a cognitive screen with a sensitivity of 0.90, meaning it catches 90 percent of true cases, and a specificity of 0.87, meaning it correctly clears 87 percent of those without the disorder. The positive predictive value, the probability that a person who screens positive truly has the disorder, is the number of true positives divided by all positives, that is sensitivity times prevalence, divided by the sum of that quantity and the false-positive rate times the complement of prevalence. Consider first a community setting where the prevalence of the disorder among those screened is 0.05. The true positives are 0.90 times 0.05, which is 0.045. The false positives are the false-positive rate, 1 minus 0.87 or 0.13, times the 0.95 who are unaffected, which is 0.1235. The positive predictive value is therefore 0.045 divided by the sum of 0.045 and 0.1235, that is 0.045 divided by 0.1685, or about 0.267. In other words, at a community base rate barely a quarter of positive screens are true cases, and nearly three in four are false alarms. Now move the same test to a memory clinic where half of those tested are impaired, so the prevalence is 0.50. The true positives are 0.90 times 0.50, or 0.45; the false positives are 0.13 times 0.50, or 0.065; and the positive predictive value is 0.45 divided by 0.515, or about 0.874. The identical test, unchanged in sensitivity and specificity, has gone from misleading to trustworthy purely because the base rate rose. This is why a screen is a triage tool rather than a diagnosis, and why the same positive result means one thing in a health fair and quite another in a clinic.

Discussion

Cognition disorders matter first as the boundary case of cognitive psychology itself: they are what the study of normal cognition looks like when it fails, and the pattern of failure is evidence about the architecture of the intact mind. That memory can collapse while language is spared, or social cognition erode while memory holds, is part of the case that these are separable systems rather than facets of one general faculty. The category matters second because its modern framework embodies a hard-won conceptual shift, from a categorical view in which a person either has dementia or does not, to a graded continuum on which the decisive line is functional rather than psychometric (Sachdev et al., 2014). Drawing the boundary at independence rather than at a score is a claim about what a disorder is for: it locates the disorder in the person's life, not in the test. The category matters third because it is where cognitive science meets its own base rates. The screening logic worked through above is not a technicality but the central discipline of the field, the reason a positive test is a question rather than an answer, and misreading it, in either direction, does real harm (Petersen et al., 1999). And it matters, finally, because the biology is now moving underneath the syndrome: as diseases like Alzheimer's become biologically defined, the relationship between a pathology and the cognitive disorder it produces is itself becoming a research question rather than a settled identity (Jack et al., 2018).

Common Misconceptions

Dementia is a normal, inevitable part of getting old.

A major neurocognitive disorder is a decline beyond what aging explains, caused by disease rather than by age itself, and a large share of dementia risk is tied to modifiable factors across the lifespan (Livingston et al., 2020). Ordinary aging slows processing and taxes memory, but it does not, on its own, strip a person of the independence that defines the major disorder (Sachdev et al., 2014).

Mild cognitive impairment always progresses to dementia.

Mild cognitive impairment is a risk state, not an early stage with a fixed destination: a portion of those who have it progress each year, but many remain stable and some revert to normal cognition (Petersen, 2004; Gauthier et al., 2006). Treating the label as a diagnosis of impending dementia mistakes elevated risk for certainty.

A low score on a cognitive screen means a person has dementia.

What a positive screen means depends on how common the disorder is among those tested, and at a low community base rate most positives are false alarms (Petersen et al., 1999). A screen selects a person for fuller assessment; the diagnosis rests on neuropsychological testing, a history of decline, and often biomarkers, not on the screen alone (Nasreddine et al., 2005).

Glossary

Amnestic mild cognitive impairment.

The subtype of mild cognitive impairment in which memory is the domain principally affected, carrying the highest risk of progression to Alzheimer's dementia.

Biomarker.

A measurable indicator of a disease process, such as amyloid, tau, or neurodegeneration in Alzheimer's disease, that can be detected during life.

Cognitive domain.

One of the six broad areas of thinking the DSM-5 uses to specify a neurocognitive disorder: complex attention, executive function, learning and memory, language, perceptual-motor function, and social cognition.

Delirium.

An acute, fluctuating disturbance of attention and awareness, developing over hours to days, that is often reversible once its underlying cause is treated.

Dementia.

The traditional term for a major neurocognitive disorder, a decline severe enough to compromise independence in everyday activities.

Executive function.

The set of control processes, including planning, working memory, flexibility, and inhibition, that guide goal-directed behaviour and form one of the six domains.

Functional independence.

The capacity to manage instrumental daily activities without help, the criterion that separates a mild neurocognitive disorder from a major one.

Major neurocognitive disorder.

The DSM-5 term for dementia: an acquired decline severe enough to interfere with independence in everyday activities.

Mild cognitive impairment.

An objective, measurable cognitive decline in a person who remains functionally independent, a risk state for dementia that maps onto the mild neurocognitive disorder.

Mild neurocognitive disorder.

The DSM-5 category for a modest but objective cognitive decline that does not yet compromise everyday independence.

Mini-Mental State Examination.

A brief thirty-point cognitive screen introduced in 1975, widely used but relatively insensitive to mild and non-memory deficits.

Montreal Cognitive Assessment.

A brief cognitive screen designed to be more sensitive to mild cognitive impairment by sampling executive function, attention, and delayed recall.

Neurocognitive disorder.

The DSM-5 family name for acquired disorders of cognition, graded from mild to major and specified by the domains affected.

Neuropsychological assessment.

Detailed, standardised testing across cognitive domains that characterises the profile of impairment and supports a diagnosis a brief screen cannot settle.

Positive predictive value.

The probability that a person who screens positive truly has the disorder, which rises with the prevalence among those tested.

Prevalence.

The proportion of a tested population who have the disorder, the base rate that determines what a positive screen is worth.

Sensitivity and specificity.

The proportion of true cases a test correctly flags and the proportion of unaffected people it correctly clears; fixed properties of a test that, unlike predictive value, do not depend on prevalence.

Key Researchers

Serge Gauthier. Professor Emeritus of Neurology and Neurosurgery, Psychiatry, and Medicine at McGill University, where he directed the Alzheimer Disease Research Unit; he helped define the international consensus on mild cognitive impairment as the target for early detection and intervention. Faculty Page - ORCID - Google Scholar

Sharon K. Inouye. Professor of Medicine at Harvard Medical School and Director of the Aging Brain Center at the Hinda and Arthur Marcus Institute for Aging Research; she developed the Confusion Assessment Method and shaped the modern understanding of delirium in older adults. Faculty Page - ORCID - Wikipedia

Ziad S. Nasreddine. Behavioural neurologist and founder of the MoCA Clinic in Greenfield Park, Quebec; he created the Montreal Cognitive Assessment, now one of the most widely used brief screens for mild cognitive impairment. ORCID - Wikipedia

Ronald C. Petersen (b. 1946). Cortez Professor of Neurology at the Mayo Clinic and Director of the Mayo Clinic Alzheimer's Disease Research Center; his work established mild cognitive impairment as a clinical entity and set its diagnostic criteria. Faculty Page - Wikidata

Perminder S. Sachdev (b. 1956). Scientia Professor of Neuropsychiatry at UNSW Sydney and Co-Director of the Centre for Healthy Brain Ageing; he helped lead the DSM-5 work that recast the cognition disorders as the graded family of neurocognitive disorders. Faculty Page - ORCID - Google Scholar - Wikipedia

Frequently Asked Questions

What is a cognition disorder?
A cognition disorder is a condition in which acquired brain injury or disease measurably degrades one or more domains of thinking, such as memory, attention, language, or executive control, beyond what normal aging would explain (Sachdev et al., 2014). In current diagnostic language these are the neurocognitive disorders, and they are defined by an objective decline from a person's own former level, not by a low score alone.

What is the difference between a mild and a major neurocognitive disorder?
The difference is functional independence, not the test score (Sachdev et al., 2014). In a mild neurocognitive disorder the deficits are measurable but the person still manages everyday activities on their own, whereas in a major neurocognitive disorder, the condition long called dementia, the deficits are severe enough to compromise that independence (Ganguli et al., 2011).

Is mild cognitive impairment the same as early dementia?
No. Mild cognitive impairment is a risk state, not early dementia (Petersen, 2004). Many people with it progress to dementia over the following years, but a large fraction remain stable and some return to normal cognition, so the label marks elevated risk rather than an inevitable course (Gauthier et al., 2006).

How are cognition disorders screened and diagnosed?
Brief bedside tests such as the Mini-Mental State Examination and the Montreal Cognitive Assessment flag people who may need fuller evaluation (Folstein et al., 1975; Nasreddine et al., 2005). A diagnosis rests on a fuller picture, including detailed neuropsychological testing, a history of decline, and increasingly biomarkers of the underlying disease (Jack et al., 2018).

What causes cognition disorders?
Many diseases can, including Alzheimer's disease, cerebrovascular disease, Lewy body disease, and frontotemporal degeneration, and biomarkers now let some of these causes be identified during life (Jack et al., 2018; Bondi et al., 2017). A share of late-life risk is also attributable to modifiable factors across the lifespan (Livingston et al., 2020).

How is delirium different from dementia?
Delirium is an acute, fluctuating disturbance of attention and awareness that develops over hours or days and is often reversible once its cause is treated, whereas dementia is a chronic, gradually progressive loss (Inouye et al., 2014). The two often coexist, and delirium in a vulnerable person can be the first sign of an underlying dementia.

Can cognition disorders be prevented?
Not with certainty, but a large share of dementia risk is linked to modifiable factors, including hearing loss, less education, hypertension, physical inactivity, and social isolation, so acting on them lowers risk at the population level (Livingston et al., 2020). Prevention shifts the odds; it does not guarantee an outcome for any one person.

Does a positive cognitive screening test mean a person has dementia?
No. What a positive screen means depends on how common the disorder is among the people tested (Sachdev et al., 2014). At a low community base rate most positive screens are false alarms, which is why a positive result selects a person for fuller assessment rather than settling the diagnosis (Petersen et al., 1999).

Support Organizations

Organizations that provide information, assessment guidance, and support for people affected by cognition disorders and their families.

References